JP2008542440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542440A5 JP2008542440A5 JP2008515384A JP2008515384A JP2008542440A5 JP 2008542440 A5 JP2008542440 A5 JP 2008542440A5 JP 2008515384 A JP2008515384 A JP 2008515384A JP 2008515384 A JP2008515384 A JP 2008515384A JP 2008542440 A5 JP2008542440 A5 JP 2008542440A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- use according
- pain
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 33
- 208000002193 Pain Diseases 0.000 claims 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 208000000094 Chronic Pain Diseases 0.000 claims 5
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 101150111783 NTRK1 gene Proteins 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000025661 ovarian cyst Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000290A ITRM20050290A1 (it) | 2005-06-07 | 2005-06-07 | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| ITRM2005A000290 | 2005-06-07 | ||
| PCT/IT2006/000427 WO2006131952A1 (en) | 2005-06-07 | 2006-06-07 | Novel analgesic treatment with prolonged effect |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013037304A Division JP2013151509A (ja) | 2005-06-07 | 2013-02-27 | 延長効果をもつ新規鎮痛治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008542440A JP2008542440A (ja) | 2008-11-27 |
| JP2008542440A5 true JP2008542440A5 (cg-RX-API-DMAC7.html) | 2009-07-23 |
| JP5730464B2 JP5730464B2 (ja) | 2015-06-10 |
Family
ID=37056613
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008515383A Expired - Fee Related JP5133879B2 (ja) | 2005-06-07 | 2006-06-07 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
| JP2008515384A Expired - Fee Related JP5730464B2 (ja) | 2005-06-07 | 2006-06-07 | 延長効果をもつ新規鎮痛治療 |
| JP2012106277A Withdrawn JP2012158604A (ja) | 2005-06-07 | 2012-05-07 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
| JP2013037304A Pending JP2013151509A (ja) | 2005-06-07 | 2013-02-27 | 延長効果をもつ新規鎮痛治療 |
| JP2014163809A Pending JP2014218513A (ja) | 2005-06-07 | 2014-08-11 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008515383A Expired - Fee Related JP5133879B2 (ja) | 2005-06-07 | 2006-06-07 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012106277A Withdrawn JP2012158604A (ja) | 2005-06-07 | 2012-05-07 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
| JP2013037304A Pending JP2013151509A (ja) | 2005-06-07 | 2013-02-27 | 延長効果をもつ新規鎮痛治療 |
| JP2014163809A Pending JP2014218513A (ja) | 2005-06-07 | 2014-08-11 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8691221B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2484380A1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP5133879B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101486085B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101277718B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006256387B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2610596A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1890726T3 (cg-RX-API-DMAC7.html) |
| IT (1) | ITRM20050290A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007015487A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20080084L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ564071A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2427387C2 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2006131952A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| EP2129401B8 (en) * | 2006-12-21 | 2020-01-15 | Amgen Inc. | Stable buffered formulations containing polypeptides |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| MY153781A (en) | 2007-08-10 | 2015-03-13 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| KR20130087632A (ko) | 2007-12-17 | 2013-08-06 | 화이자 리미티드 | 간질성 방광염의 치료 |
| DK2252633T3 (da) * | 2008-02-04 | 2013-11-11 | Lay Line Genomics Spa | Anti-TrkA antistoffer og derivater deraf |
| BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| AU2009256246B2 (en) | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
| BRPI0915448A2 (pt) | 2008-07-08 | 2015-11-10 | Abbott Lab | imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas |
| EP2331090B1 (en) | 2008-09-19 | 2018-01-03 | Pfizer Inc. | Stable liquid antibody formulation |
| DK2350075T3 (da) | 2008-09-22 | 2014-05-26 | Array Biopharma Inc | Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer |
| EP2350071B1 (en) | 2008-10-22 | 2014-01-08 | Array Biopharma, Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
| US9040508B2 (en) * | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
| SG173620A1 (en) | 2009-02-17 | 2011-09-29 | Ucb Pharma Sa | Antibody molecules having specificity for human ox40 |
| EP2448970B1 (en) * | 2009-05-04 | 2014-07-09 | Abbott Research B.V. | Antibodies against nerve growth factor (ngf) with enhanced in vivo stability |
| WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| JP2013503607A (ja) * | 2009-09-01 | 2013-02-04 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
| MX2012004415A (es) * | 2009-10-15 | 2012-05-08 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| SG183983A1 (en) * | 2010-03-17 | 2012-10-30 | Abbott Res Bv | Anti-nerve growth factor (ngf) antibody compositions |
| DK2918588T3 (en) | 2010-05-20 | 2017-08-28 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| JP2013537415A (ja) | 2010-08-03 | 2013-10-03 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| US9505829B2 (en) | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
| CN103260639A (zh) | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| MX359070B (es) | 2010-12-01 | 2018-09-13 | Alderbio Holdings Llc | Composiciones anti-ngf y uso de las mismas. |
| EP4026845A1 (en) | 2011-05-06 | 2022-07-13 | Zoetis Services LLC | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| GB201114858D0 (en) * | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
| MY161394A (en) * | 2011-05-06 | 2017-04-14 | Nexvet Australia Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| US9580496B2 (en) * | 2011-05-06 | 2017-02-28 | Nexvet Australia Pty Ltd | Therapeutic canine immunoglobulins and methods of using same |
| CA2835094C (en) * | 2011-05-06 | 2020-12-22 | David Gearing | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| CN103764677A (zh) | 2011-05-06 | 2014-04-30 | Nvip私人有限公司 | 抗神经生长因子抗体及其制备和使用方法 |
| TR201904088T4 (tr) | 2011-05-20 | 2019-05-21 | Alderbio Holdings Llc | Anti-CGRP bileşimleri ve bunların kullanımları. |
| DK2709663T3 (da) | 2011-05-20 | 2019-05-20 | Alderbio Holdings Llc | Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere |
| NZ717704A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| WO2013009582A1 (en) | 2011-07-12 | 2013-01-17 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| US8926978B2 (en) | 2011-10-25 | 2015-01-06 | Anaptysbio, Inc. | Antibodies directed against nerve growth factor (NGF) |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| UY34558A (es) | 2011-12-30 | 2013-07-31 | Abbvie Inc | Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17 |
| AU2013207346A1 (en) * | 2012-01-05 | 2014-06-05 | Beech Tree Labs, Inc. | Method of treating pain by administration of Nerve Growth Factor |
| WO2013176970A1 (en) | 2012-05-22 | 2013-11-28 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| ES2894852T3 (es) | 2012-06-06 | 2022-02-16 | Zoetis Services Llc | Anticuerpos anti-NGF caninizados y métodos de los mismos |
| AU2013273115B2 (en) * | 2012-06-08 | 2018-03-01 | Ichnos Sciences SA | Humanized anti-TrkA antibodies with amino acid substitutions |
| EP2674439B1 (en) | 2012-06-13 | 2017-02-01 | Rottapharm Biotech S.r.l. | Anti-TrkA antibodies, derivatives and uses thereof |
| KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| AU2014227732A1 (en) | 2013-03-15 | 2015-09-17 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 beta and IL-17 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| WO2015039334A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| WO2015039333A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| RS61968B1 (sr) | 2014-02-05 | 2021-07-30 | VM Oncology LLC | Sastavi jedinjenja i njihova primena |
| WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| TWI767858B (zh) | 2014-11-16 | 2022-06-11 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| MA41097A (fr) * | 2014-12-05 | 2017-10-10 | Glenmark Pharmaceuticals Sa | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| WO2016116900A1 (en) | 2015-01-23 | 2016-07-28 | Gvk Biosciences Private Limited | Inhibitors of trka kinase |
| WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| AU2016270803A1 (en) | 2015-06-01 | 2018-01-04 | Loxo Oncology, Inc. | Methods of diagnosing and treating cancer |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| SG11201803438XA (en) | 2015-10-26 | 2018-05-30 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| JP7057343B2 (ja) | 2016-04-04 | 2022-04-19 | ロクソ オンコロジー， インコーポレイテッド | 小児癌の処置方法 |
| PE20181888A1 (es) | 2016-04-04 | 2018-12-11 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| HUE053643T2 (hu) | 2016-05-18 | 2021-07-28 | Loxo Oncology Inc | (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| AR114110A1 (es) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
| EP3765499A1 (en) | 2018-03-12 | 2021-01-20 | Zoetis Services LLC | Anti-ngf antibodies and methods thereof |
| US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| US12180207B2 (en) | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
| KR20210113597A (ko) | 2019-01-08 | 2021-09-16 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용한 두통의 급성 치료 및 신속 치료 |
| CN114230663B (zh) * | 2019-05-30 | 2022-09-27 | 广东东阳光药业有限公司 | TrkA的抗体及其应用 |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| AU2020204105B2 (en) * | 2020-06-19 | 2023-06-08 | Dartsbio Pharmaceuticals Ltd. | Anti-human ngf antibodies and methods using same |
| US11655292B2 (en) | 2020-06-23 | 2023-05-23 | Ampsource Biopharma Shanghai Inc. | Anti-human NGF antibodies and methods using same |
| EP4308101A1 (en) * | 2021-04-21 | 2024-01-24 | Redyneuheart S.r.l. | N-acetyl cysteine for neuraxial use as a trka tyrosine kinase receptor inhibitor for the treatment of acute and chronic pain |
| WO2023034880A2 (en) | 2021-08-31 | 2023-03-09 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| EP4457246A4 (en) | 2021-12-28 | 2025-11-19 | 4B Tech Suzhou Limited | TRKA ANTIBODIES AND THEIR APPLICATION |
| EP4316481A1 (en) | 2022-08-01 | 2024-02-07 | Edmond Pharma S.R.L. | Erdosteine, salts, enantiomers or metabolites thereof for use in the treatment of acute and chronic pain states |
| US20250122291A1 (en) | 2023-10-13 | 2025-04-17 | Cephalon Llc | Anti-trka antibodies and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4230691A (en) * | 1978-05-23 | 1980-10-28 | The Massachusetts General Hospital | Nerve growth factor antibody and process |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SE465573B (sv) | 1989-03-14 | 1991-09-30 | Lope Medicine Ab | Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor |
| US5147294A (en) * | 1990-10-01 | 1992-09-15 | Trustees Of Boston University | Therapeutic method for reducing chronic pain in a living subject |
| AU9059991A (en) | 1990-11-13 | 1992-06-11 | Children's Medical Center Corporation | Controlling beta-amyloid related neuronal degeneration by antagonizing NGF-effected neuronal activity |
| EP0559834A1 (en) | 1990-11-30 | 1993-09-15 | Abbott Laboratories | Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| IL104620A (en) | 1992-02-06 | 2000-02-29 | Schering Plough Corp | Humanized monoclonal antibodies against human interleukin-5 |
| EP0578515A3 (en) | 1992-05-26 | 1995-05-10 | Bristol Myers Squibb Co | Humanized monoclonal antibodies. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| GB9402331D0 (en) * | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
| US5877016A (en) * | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5747060A (en) * | 1996-03-26 | 1998-05-05 | Euro-Celtique, S.A. | Prolonged local anesthesia with colchicine |
| DE19732928C2 (de) * | 1997-07-31 | 2000-05-18 | Gruenenthal Gmbh | Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel |
| US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| CA2388341A1 (en) | 1999-08-06 | 2001-02-15 | S.I.S.S.A. Scuola Internazionale Superiore Di Studi Avanzati | Non-human transgenic animals for the study of neurodegenerative syndromes |
| EP1265605B1 (en) * | 2000-01-18 | 2006-09-27 | McGILL UNIVERSITY | Pharmaceutical compositions comprising beta-turn peptidomimetic cyclic compounds |
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| AU5081401A (en) | 2000-03-16 | 2001-10-03 | Genentech Inc | Anti-tissue factor antibodies with enhanced anticoagulant potency |
| FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| JP2004517049A (ja) | 2000-09-01 | 2004-06-10 | グラクソ グループ リミテッド | チロシンキナーゼ阻害剤としての置換オキシインドール誘導体 |
| CA2447986A1 (en) * | 2001-05-25 | 2002-12-05 | Cornell Research Foundation, Inc. | High affinity ligand for p75 neurotrophin receptor |
| MXPA03010911A (es) * | 2001-05-30 | 2004-02-17 | Genentech Inc | Anticuerpos contra ngf para el tratamiento de varios desordenes. |
| SE0102067D0 (sv) | 2001-06-11 | 2001-06-11 | A & Science Invest Ab | Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation |
| ES2338218T3 (es) * | 2001-07-25 | 2010-05-05 | Facet Biotech Corporation | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. |
| JP3729841B2 (ja) * | 2001-10-15 | 2005-12-21 | 麒麟麦酒株式会社 | 抗ｈｌａ−ｄｒ抗体の利用 |
| US6919426B2 (en) * | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| WO2004032852A2 (en) | 2002-10-04 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
| WO2005000194A2 (en) | 2002-10-08 | 2005-01-06 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| JP4584713B2 (ja) | 2002-10-08 | 2010-11-24 | ライナット ニューロサイエンス コーポレイション | 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物 |
| ES2380055T3 (es) | 2002-12-20 | 2012-05-08 | H. Lundbeck A/S | Modulación de la actividad de neurotrofinas; método de escrutinio |
| EA011479B1 (ru) * | 2002-12-24 | 2009-04-28 | Ринат Ньюросайенс Корп. | Антитело связывающееся с ngf, и способы его применения |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US20040131515A1 (en) * | 2003-01-03 | 2004-07-08 | Alexanian Ara J. | Material heat treatment system and method statement regarding federally sponsored research or development |
| US20060147932A1 (en) | 2003-01-18 | 2006-07-06 | Alun Davies | Methods of screening for modulators of nerve growth factor |
| HRP20050721A2 (en) | 2003-02-19 | 2007-03-31 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same |
| TWI382031B (zh) * | 2003-07-15 | 2013-01-11 | Amgen Inc | 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體 |
| WO2005044293A2 (en) | 2003-11-07 | 2005-05-19 | Lay Line Genomics S.P.A. | Compositions able to prevent neurodegenerative processes and methods of assaying the same |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| US7522822B2 (en) * | 2004-01-06 | 2009-04-21 | Robert Trujillo | Halogen lamp assembly with integrated heat sink |
| MXPA06011463A (es) * | 2004-04-07 | 2007-04-25 | Rinat Neuroscience Corp | Metodos para tratar dolor por cancer de hueso al administrar un antagonista de factor de crecimiento de nervio. |
| ITRM20040212A1 (it) | 2004-04-30 | 2004-07-30 | Lay Line Genomics Spa | Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce. |
| ME00226B (me) * | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| US9315571B2 (en) | 2005-01-24 | 2016-04-19 | Elan Pharma International Limited | Specific binding members for NGF |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| EP2129401B8 (en) | 2006-12-21 | 2020-01-15 | Amgen Inc. | Stable buffered formulations containing polypeptides |
| EP4119579A1 (en) | 2007-05-31 | 2023-01-18 | Genmab A/S | Stable igg4 antibodies |
| US8309088B2 (en) * | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| MY153781A (en) | 2007-08-10 | 2015-03-13 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| KR20130087632A (ko) * | 2007-12-17 | 2013-08-06 | 화이자 리미티드 | 간질성 방광염의 치료 |
| DK2252633T3 (da) | 2008-02-04 | 2013-11-11 | Lay Line Genomics Spa | Anti-TrkA antistoffer og derivater deraf |
| CA2782712A1 (en) | 2010-02-03 | 2011-08-11 | Morinaga Milk Industry Co., Ltd. | Method for manufacturing aloe powder |
| SG183983A1 (en) | 2010-03-17 | 2012-10-30 | Abbott Res Bv | Anti-nerve growth factor (ngf) antibody compositions |
-
2005
- 2005-06-07 IT IT000290A patent/ITRM20050290A1/it unknown
-
2006
- 2006-06-07 KR KR1020087000315A patent/KR101486085B1/ko not_active Expired - Fee Related
- 2006-06-07 RU RU2007147625/15A patent/RU2427387C2/ru not_active IP Right Cessation
- 2006-06-07 DK DK06756318.9T patent/DK1890726T3/en active
- 2006-06-07 EP EP11188102A patent/EP2484380A1/en not_active Withdrawn
- 2006-06-07 CN CN2006800288760A patent/CN101277718B/zh not_active Expired - Fee Related
- 2006-06-07 US US11/921,398 patent/US8691221B2/en active Active
- 2006-06-07 CA CA002610596A patent/CA2610596A1/en not_active Abandoned
- 2006-06-07 JP JP2008515383A patent/JP5133879B2/ja not_active Expired - Fee Related
- 2006-06-07 CA CA2611433A patent/CA2611433C/en active Active
- 2006-06-07 US US11/921,826 patent/US9688749B2/en not_active Expired - Fee Related
- 2006-06-07 EP EP06756317A patent/EP1893234A2/en not_active Withdrawn
- 2006-06-07 WO PCT/IT2006/000427 patent/WO2006131952A1/en not_active Ceased
- 2006-06-07 WO PCT/IT2006/000426 patent/WO2006131951A2/en not_active Ceased
- 2006-06-07 EP EP06756318.9A patent/EP1890726B1/en active Active
- 2006-06-07 JP JP2008515384A patent/JP5730464B2/ja not_active Expired - Fee Related
- 2006-06-07 NZ NZ564071A patent/NZ564071A/en not_active IP Right Cessation
- 2006-06-07 AU AU2006256387A patent/AU2006256387B2/en not_active Ceased
- 2006-06-07 MX MX2007015487A patent/MX2007015487A/es active IP Right Grant
-
2008
- 2008-01-07 NO NO20080084A patent/NO20080084L/no unknown
-
2012
- 2012-05-07 JP JP2012106277A patent/JP2012158604A/ja not_active Withdrawn
-
2013
- 2013-02-27 JP JP2013037304A patent/JP2013151509A/ja active Pending
-
2014
- 2014-08-11 JP JP2014163809A patent/JP2014218513A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008542440A5 (cg-RX-API-DMAC7.html) | ||
| JP2008542439A5 (cg-RX-API-DMAC7.html) | ||
| RU2007147625A (ru) | МОЛЕКУЛЫ, СПОСОБНЫЕ ИНГИБИРОВАТЬ СВЯЗЫВАНИЕ МЕЖДУ NGF И РЕЦЕПТОРОМ TrkA, В КАЧЕСТВЕ АНАЛЬГЕТИКОВ С ПРОЛОНГИРОВАННЫМ ЭФФЕКТОМ | |
| JP2020062036A5 (cg-RX-API-DMAC7.html) | ||
| RU2013140625A (ru) | Антитела против ангиопоэтина-2 человека | |
| JP2012511913A5 (cg-RX-API-DMAC7.html) | ||
| RU2017102193A (ru) | Конструкции полиспецифических антител | |
| WO2008055206A3 (en) | Humanized anti-factor d antibodies | |
| RU2012128651A (ru) | Антитела, связывающиеся преимущественно с внеклеточным доменом 4 человеческого csf-1r, и их применение | |
| JP2017176174A5 (cg-RX-API-DMAC7.html) | ||
| RU2012129735A (ru) | Антитела к her3 и их применения | |
| EA201100642A1 (ru) | Антитела к миостатину | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| WO2008019061A3 (en) | Anti-il-6 monoclonal antibodies and uses thereof | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2017511130A5 (cg-RX-API-DMAC7.html) | ||
| JP2017528117A5 (cg-RX-API-DMAC7.html) | ||
| JP2014533239A5 (cg-RX-API-DMAC7.html) | ||
| MY160892A (en) | Antibodies to ccr2 | |
| EA201200548A1 (ru) | Биспецифические связывающие молекулы для антиангиогенезной терапии | |
| RU2430111C3 (ru) | Молекулы антител с улучшенными свойствами | |
| JP2015514110A5 (cg-RX-API-DMAC7.html) | ||
| RU2011137369A (ru) | Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента |